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Abstract
There are many reports suggesting an association between vitamin D status and both the development of multiple sclerosis (MS) and its 
course. This relationship and the effects of vitamin D and interferon β-1b (IFNβ-1b) in the treatment of patients are reviewed in the BEtaferon/
Betaseron in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) and the Betaferon/Betaseron Efficacy Yielding Outcomes of 
a New Dose in multiple sclerosis (BEYOND) studies. In the BENEFIT study the average serum 25-hydroxyvitamin D (25[OH]D) levels strongly 
predicted MS disease activity and progression. The probability of clinically definite MS (CDMS) and magnetic resonance imaging (MRI) activity 
was lower in these clinically isolated syndrome (CIS) patients with 25(OH)D levels ≥50 nmol/L and in those starting with IFNβ -1b. Furthermore, 
there was a beneficial effect on relapse rate, occurrence of new active MRI lesions and disease progression for a 50 nmol/L increase in 
25(OH)D levels. Similarly, in relapsing-remitting (RR) MS patients from the BEYOND study serum 25(OH)D levels were inversely associated 
with MRI markers of MS activity. Genetic analysis of patients from these studies indicated that there may be a benefit in monitoring and 
managing vitamin D levels in early MS patients treated with IFNβ-1b and a cumulative number of risk alleles predict lower 25(OH)D levels in 
CIS and RRMS patients. Further studies have suggested that some of the IFNβ-1b therapeutic effects on relapse could be mediated through 
modulation of vitamin D metabolism. Thus, there seems to be a benefit on clinical and MRI measures if patients are treated with both 
vitamin D and IFNβ-1b. There is a need to further evaluate this effect in clinical trials. The relationship between vitamin D and MS disease 
activity along with the effects of vitamin D and IFNβ-1b in the treatment of MS patients is reviewed.
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There is increasing evidence that vitamin D status is associated with 
both the development of multiple sclerosis (MS) and also the modulation 
of disease activity and possibly progression. Several publications have 
reported that the risk of MS is higher in patients with low vitamin D 
intake or serum 25-hydroxyvitamin D (25[OH]D) levels, for example due 
to low sun exposure.1,2 However, the findings of studies examining the 
relationship between vitamin D and MS disease activity are difficult to 
compare as the patients enrolled often had variable disease duration 
and it has been problematic to decide if low vitamin D levels were a 
consequence of MS activity (reverse causality) or if low levels early in 
the disease can predict long-term progression and disability.3,4 
A recent publication analysed systematic reviews and meta-analyses to 
summarise the risk factors associated with MS.5 Of the 44 meta-analyses 
(416 primary studies), 11 had high significance (p<0.001). Anti-Epstein-
Barr nuclear antigen (anti-EBNA) immunoglobulin (Ig)-G seropositivity, 
infectious mononucleosis and smoking showed the strongest consistent 
evidence of an association in these high significance studies. Vitamin D 
status did not reach significance as a risk factor. However, it is important 
to note that vitamin D measured at the onset of MS may not necessarily 
reflect vitamin D levels at other significant times in a person’s life, which 
may predispose them to later development of MS. Measure of prior sun 
exposure as potential, although not absolute, proxy for vitamin D levels 
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in a Caucasian population have suggested that lifetime sun exposure, as 
well as sun exposure in the adolescent period, may be more important 
factors in MS risk than recent sun exposure.6,7 Effects of vitamin D levels 
on disease activity may be easier to assess as the exposure (vitamin D) 
is contemporaneous with the outcome (disease activity). 
Here we review the relationship between vitamin D and MS disease 
activity and the effects of vitamin D and interferon β-1b (IFNβ-1b) in 
the treatment of MS in patients from the BEtaferon/Betaseron in 
Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) and 
the Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose 
in multiple sclerosis (BEYOND) studies. Furthermore, the molecular 
mechanisms underlying the impact of vitamin D on MS disease activity 
and the possible genetic component associated with vitamin D and MS 
are considered.
Is Vitamin D Status an Early Predictor of 
Multiple Sclerosis Activity and Progression?
Clinically Isolated Syndrome Patients from the 
BENEFIT Study 
The patients were assessed in order to determine if vitamin D status 
early in the MS disease process influenced the long-term disease 
course.8 BENEFIT was a randomised, placebo-controlled, double-blind 
trial that studied patients with a first event suggestive of MS treated 
with either IFNβ -1b or placebo. Recruited patients were mostly white of 
European ancestry. The BENEFIT study was originally set up to compare 
early and delayed treatment with IFNβ -1b. To fulfil the inclusion criteria, 
patients needed a minimum of two clinically silent magnetic resonance 
imaging (MRI) lesions. The placebo-randomised patients remained on 
placebo for 2 years or until a second clinical event occurred and a 
diagnosis of clinically definite MS (CDMS) could be made. All patients 
were eligible to enter a prospectively planned follow-up when they 
received open-label IFNβ-1b for up to 5 years after randomisation. Table 
1 summarises selected characteristics of BENEFIT participants, the 
baseline characteristics were similar between patients with 25(OH)D 
levels <50 nmol/L and ≥50 nmol/L, except for the median number of T2 
lesions, which were higher in the lower 25(OH)D group. Serum samples 
were collected at baseline, 6, 12 and 24 months for the measurement 
of 25(OH)D levels. Most statistical analyses were restricted to patients 
who had 25(OH)D measured at 6 and 12 months to reduce bias from 
seasonal variation, as the seasonally synchronous baseline, 12-month 
and 24-month samples could give a biased estimate of the year-round 
status of vitamin D. The clinical and MRI assessments of time to a 
definite diagnosis of MS, MS activity and MS progression were analysed. 
MS activity was assessed as the number of relapses and new active 
lesions on brain MRI, while percentage change in T2 lesion volume and 
the percentage change of brain volume represented MRI markers of 
progression. Clinically, progression was determined by the Expanded 
Disability Status Score (EDSS) score over time, with month 6 as the 
primary reference point. All analyses were adjusted for sex, age at 
baseline, treatment at randomisation, baseline T2 lesion score and type 
of clinically isolated syndrome (CIS) (monofocal versus multifocal). 
Patients with higher 25(OH)D levels, were generally younger, with a 
lower BMI, smaller number of T2 lesions, smaller T2 lesion volume and 
higher brain volume at CIS. In total, 46.6 % of patients converted to 
CDMS and this was strongly related to serum 25(OH)D. 
In the first 12 months after CIS, the average serum 25(OH)D level strongly 
predicted MS activity and progression in the subsequent 4 years. The 
probability of CDMS was lower in the group of patients with levels of 
25(OH)D ≥50 nmol/L and in the subgroup of patients starting with IFNβ-
1b from randomisation compared with those with levels <50  nmol/L 
(p=0.048 and p=0.0043 after 1 year for all patients and IFNβ-1b-treated 
patients, respectively). Furthermore, MRI activity, defined as the 
cumulative number of new active lesions (new or enlarging T2 lesions, 
new gadolinium-enhancing lesions), was significantly reduced in all 
patients and in the subgroup of patients treated with IFNβ-1b from 
randomisation with ≥50 nmol/L 25(OH)D levels versus those with levels 
<50 nmol/L (p=0.002; p=0.0055, respectively) (see Figures 1 and 2). In 
addition, the percent change in T2 lesion volume and brain volume were 
strongly inversely associated with 25(OH)D levels (p=0.008 and 0.005, 
respectively) and the subgroup of patients starting with early treatment 
with IFNβ-1b (p=0.016 and 0.0037, respectively). Furthermore, there was 
no difference in the number of patients with plasma 25(OH)D <50 nmol/L 
or ≥50 nmol/L reporting flu-like symptoms at 6 and 12 months.9,10 
Patients were also assessed according to their 25(OH)D levels in 
increments of 50 nmol/L. Overall, there was also a non-significant 
27  % decrease in relapse rate for a 50  nmol/L increment in 25(OH)
D. This association was stronger among patients at both 6 and 12 
months; in this group a significantly lower relapse rate with increasing 
serum 25(OH)D was observed after 12 months. The rate of occurrence 
of new active MRI lesions decreased with increasing serum 25(OH)D 
and a 50  nmol/L increase in the average 25(OH)D level significantly 
predicted a lower number of lesions. Measures of MS progression 
(change in brain volume, T2 lesion volume and EDSS score) were also 
inversely associated with increased 25(OH)D with each indicating 
a beneficial effect. For a 50 nmol/L increase in 25(OH)D, the rate of 
brain volume loss was lower by 0.27 % (p=0.12), T2 lesion volume 
decreased by 20 %/ year (p<0.001) and average EDSS score reduced 
by 0.16 steps (p=0.11). 
Although associations were generally stronger for MRI than for clinical 
outcomes, the latter were still remarkable considering the overall low 
rate of relapses (0.2 per year) and small EDSS score change (median 
change, 0.0) in BENEFIT. The results emphasise the importance of 
identifying and correcting 25(OH)D insufficiency early in the course 
of MS and also indicate that early treatment with IFNβ-1b has 
an additive effect with 25(OH)D to reduce disease severity and 
progression in both clinical and imaging outcomes without impacting 
tolerability to IFNβ-1b.
Table 1: Selected Characteristics at Baseline 
by Average 25(OH)D levels at 12 Months – 
BENEFIT Study 
 25(OH)D  25(OH)D
 <50 nmol/L ≥50 nmol/L
Number of patients*  251 213
25(OH)D, median (range), nmol/L 39 (19–50) 60 (50–98)
Age at recruitment, mean (SD), years 31.3 (7.6) 30.1 (7.2)
Female, % 71.1 70.0
Randomised to IFNβ-1b, % 59.8 65.3
Monofocal onset, % 52.6 52.1
Number of T2 lesions at baseline, median (Q1–Q3) 20 (8–38) 15 (7–37)
*n=464 patients as one patient only had 25-hydroxyvitamin D (25(OH)D) measures at 
24 months. The baseline characteristics were similar between patients with 25(OH)D 
levels <50 nmol/L and ≥50 nmol/L except for the median number of T2 lesions, which 
were higher in the lower 25(OH)D group. BENEFIT = BEtaferon/Betaseron in Newly 
Emerging multiple sclerosis For Initial Treatment. Source: reproduced with permission 
from Ascherio et al., 2014.8
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Relapsing-remitting Multiple Sclerosis Patients 
from the BEYOND Study
The BEYOND study included patients from Western and Eastern 
Europe, North America and the Southern hemisphere who had been 
diagnosed with relapsing-remitting MS (RRMS) using the McDonald 
2001 criteria and were treatment naïve. The regional subgroup 
baseline characteristics are summarised in Table 2.11 The three 
study arms were treatment with IFNβ-1b (either 500 µg or 250 µg) or 
glatiramer acetate (GA) 20 mg and the mean time on study was 2.3 
years.11 Blood samples from the two IFNβ-1b arms were analysed to 
determine the impact of averaged vitamin D levels on MS disease 
course. The GA group was not included in the analysis. In total, 1,482 
patients had at least two 25(OH)D measurements 6 months apart. For 
25(OH)D status, the primary exposure variable was the cumulative 
average of season-adjusted 25(OH)D values up to 12 months with 
the adjustment performed within each region. Season adjustment 
was completed as described previously.2 The 50 nmol/L increments 
and also the <37.5, 37.5–49.9, 50–<74.9, 75–99.9 and ≥100 nmol/L 
were compared.
The multivariate statistical analysis was adjusted for age, gender, disease 
duration, region of residence, baseline EDSS and treatment dose. Cross-
sectional analysis compared season-adjusted 25(OH)D versus baseline 
MRI and versus 12-month MRI. Finally, longitudinal analysis compared 
the season-adjusted 25(OH)D levels in first year with clinical/MRI 
disease course during the study.
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Figure 1: Levels of 25(OH) Vitamin D ≥50 nmol/L Significantly Reduced the Risk of CDMS in the 
BENEFIT Study 
Figure 2: Levels of 25(OH) Vitamin D ≥50 nmol/L Significantly Reduced Magnetic Resonance 
Imaging Activity in the BENEFIT Study 
25(OH)D = 25-hydroxyvitamin D; BENEFIT= BEtaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment; CDMS = clinically definite multiple sclerosis. 
Source: reproduced with permission from Ascherio et al., 2014.8
BENEFIT= BEtaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment; CI = confidence interval; MRI = magnetic resonance imaging; SEM = standard error of the 
mean. Source: reproduced with permission from Ascherio et al., 2014.8
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The 25(OH)D levels were lowest in Eastern Europe and highest in 
Australia, Brazil and North America – as expected levels reflected the 
seasonal variation in sunlight for each region. Significant differences 
were also observed in several clinical parameters. Younger age, 
higher volume of T2 hyperintense lesions and longer disease duration 
were seen in Eastern Europe and Russia compared with Western 
Europe and North America. In the cross-sectional analyses adjusted 
for age, sex, treatment group (IFNβ-1b 250 versus 500 µg), baseline 
EDSS score, disease duration, region of residence, baseline 25(OH)
D levels, reported as estimates (95 % confidence interval [CI]) were 
inversely associated with T2 lesion volume with a 50 nmol/L higher 
level corresponding to a difference of -0.11 cm3 (log T2 lesion volume) 
-0.20 to -0.02; p=0.02, and the total number of T1-enhancing lesions 
-0.24, -0.45 to -0.02; p=0.03 at baseline. The association between 
25(OH)D and MRI parameters at 12  months gave similar results, 
with a difference in log T2 lesion volume of -0.19 cm3, -0.31 to 0.07; 
p=0.003. The difference at 12 months for log T1 hypointense lesion 
volume was -0.07 cm3, -0.14 to 0.00; p=0.055 and during year 1 the 
rate of T2 lesion count 0.78, 0.62 to 0.99; p=0.04. Furthermore, 25(OH)
D levels were also inversely associated with the cumulative number 
of new active lesions (the sum of new T2 lesions and T1-enhancing 
lesions) between baseline and 12 months (0.76, 0.60 to 0.98; p=0.03). 
In longitudinal analysis, the relative rate (RR) of cumulative new active 
lesions was reduced by 31 % (RR 0.69, 95% CI, 0.55–0.86; p=0.001) for 
each 50 nmol/L increase in 25(OH)D level in all patients. This inverse 
association was also strong and significant in analyses restricted to 
patients with 25(OH)D levels greater than 50 nmol/L (RR 0.62; 95 % 
CI, 0.46–0.84; p=0.002), and was consistently observed in each of the 
four regions (see Figure 3).
In the cross-sectional analysis between baseline 25(OH)D levels and the 
number of relapses in the previous 2 years, no significant association 
was observed. However, baseline 25(OH)D level was inversely 
associated with EDSS scores at baseline with a 50 nmol/L higher level 
of 25(OH)D corresponding to a mean difference of 0.28 in EDSS scores 
(95 % CI, -0.40 to -0.16; p<0.001). 
In summary, in these RRMS patients, serum 25(OH)D levels were 
inversely associated with MRI markers of MS activity and there was 
a similar magnitude across geographic regions despite differences in 
average levels. Furthermore, the association was similar in different 
patient subgroups according to demographic or clinical characteristics. 
The associations between 25(OH)D and relapses or clinical progression 
were not significant, which may be due to the low relapse rate as well 
as a relatively short follow-up. 
Another study investigated whether higher levels of 25(OH)D 
were protective in patients treated with GA compared with IFNβ 
(Comprehensive Longitudinal Investigation of Multiple Sclerosis at the 
Brigham and Women’s Hospital, Partners MS Center [CLIMB] study).12 
Levels of 25(OH)D were determined in 247 RRMS patients treated with 
either GA or IFNβ as their first disease-modifying drug (DMD). Higher 
25(OH)D significantly predicted longer time to first event (clinical and 
MRI endpoint) in the IFN group (p=0.013), but not with GA (p=0.38). 
Table 2: Selected Characteristics of Participants (250 and 500 µg) by Region of Recruitment – 
BEYOND Study
 Argentina Australia Brazil Western Mediterranean Scandinavia Russia Eastern North  p Value
    Europe    Europe America
Number 49 28 62 220 164 29 180 295 429
Season-adjusted 25(OH)D, nmol/L
Mean (SD) 54.2 (19.5) 67.4 (22.3) 72.1 (20.5) 58.2 (24.7) 61.8 (24.5) 62.7 (21.8) 43.4 (14.0) 52.5 (19.0) 65.4 (30.1) <0.0001
Median (IQR) 54.6 (28.9) 66.4 (18.8) 68.9 (3.7) 53.5 (39.7) 58.2 (32.6) 54.1 (28.4) 41.9 (20.0) 50.1 (22.4) 59.7 (35.8)
% male 41 14 24 34 35 24 28 32 26 0.05
Age, mean (SD), years 37.2 (9.5) 36.0 (9.0) 32.9 (9.0) 35.7 (9.4) 35.8 (9.0) 26.7 (7.1) 35.9 (9.7) 32.2 (82) 38.7 (9.0) <0.0001
Age at onset,  30.6 (8.5) 31.0 (8.9) 29.9 (9.2) 31.4 (9.3) 31.1 (8.9) 31.4 (7.3) 29.3 (9.3) 27.7 (7.8) 34.4 (9.1) <0.0001 
mean (SD), years
BMI (kg/m2), mean (SD) 25.1 (4.6) 25.5 (4.8) 25.1 (4.7) 25.4 (5.0) 24.4 (4.4) 23.9 (3.4) 23.3 (4.0) 23.1 (3.9) 28.3 (6.8) <0.0001
Baseline Disease Characteristics
EDSS (SD) 2.9 (1.4) 2.4 (1.0) 2.5 (1.2) 2.0 (1.0) 2.0 (1.1) 1.9 (1.2) 3.1 (1.1) 2.5 (1.1) 2.3 (1.1) <0.0001
Number of relapses in 2.0 (1.0) 2.3 (0.9) 2.4 (1.1) 1.8 (0.9) 1.9 (0.9) 1.9 (0.7) 2.4 (1.1) 2.1 (1.01) 1.9 (0.9) 0.0002 
past year (at baseline),  
mean (SD)
Disease duration, 7.1 (6.2) 5.6 (6.5) 3.6 (3.3) 4.8 (5.0) 5.2 (5.6) 5.8 (6.1) 7.2 (6.6) 5.1 (5.1) 4.8 (6.2) <0.0001 
median (IQR)
MSSS, mean (SD) 4.8 (2.7) 4.8 (2.4) 5.4 (2.6) 3.9 (2.3) 3.8 (2.4) 3.6 (2.4) 5.2 (2.2) 4.9 (2.1) 4.8 (2.5) <0.0001
Volume of T2 13.4 (12.9) 7.5 (9.2) 9.0 (8.7) 7.4 (7.9) 7.7 (7.9 7.5 (8.5) 13.2 (13.4) 11.7 (12.2) 6.7 (8.8) <0.0001 
hyper-intense 
lesions, mean (SD), cm3
Volume of T1 2.8 (3.2) 1.7 (2.8) 1.3 (2.6) 1.3 (2.1) 1.4 (2.1) 1.5 (2.3) 3.1 (5.2) 2.2 (3.6) 1.1 (2.7) <0.0001 
non-enhancing T1 
hypointense lesions, 
mean (SD), cm3
T1-enhancing lesions,  4 (5) 1.9 (3) 3.4 (8.0) 2.0 (1) 1.8 (2) 1.3 (1) 3.1 (7.0) 3.0 (3) 1.8 (4.0) 0.0005 
median (IQR)
Normalised brain 1,452 (130) 1,529 (84) 1,517 (98.9) 1,501 (110) 1,475 (100) 1,500 (106) 1,468 (114) 1,473 (114) 1,503 (108) <0.0001 
volume, mean (SD), cm3
25(OH)= 25-hydroxyvitamin; BEYOND = Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in multiple sclerosis; BMI = body mass index; EDSS= Expanded Disability 
Status Score; IQR = interquartile range; MSSS = Multiple Sclerosis Severity Score; SD = standard deviation. Source: Reproduced with permission from Fitzgerald et al., 2015.
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Impact of Vitamin D on Multiple Sclerosis 
Disease Activity
A global gene expression analysis of the patients from BENEFIT showed 
that 25(OH)D regulates the expression dynamics of a large gene–gene 
interaction system, which primarily regulates immune modulatory 
processes modulating MS activity.13 A decrease in MS activity was 
observed with increasing 25(OH)D levels. A number of known targets 
of IFNβ-1b and a regulator of sphingosine-1-phosphate bioavailability 
were identified in the complex network of genes regulated by 25(OH)
D. These results indicate a possible benefit in early MS patients treated 
with IFNβ-1b, of monitoring and managing vitamin D levels.
Genetic Modification of 25(OH)D Levels in 
Multiple Sclerosis
Candidate single nucleotide polymorphisms (SNPs) were analysed 
by genome-wide association studies (GWAS) to assess their impact 
on 25(OH)D levels in IFNβ-1b-treated CIS and RRMS patients from the 
BENEFIT and BEYOND trials (n= 815).14
 
All assessed candidate SNPs in DHCR7 (7-dehydrocholesterol 
reductase), GC (vitamin D binding protein) and CYP2R1 (cytochrome 
P450, family 2, subfamily R, polypeptide 1) genes were significantly 
associated with 25(OH)D levels (p≤0.05). Furthermore, a 25(OH)D risk 
score to indicate the odds ratio of being 25(OH)D deficient was derived 
from the cumulative count of risk alleles per patient. As the number 
of risk alleles increased, levels of 25(OH)D decreased (see Figure 4). 
The findings indicated that the effects of multiple risk alleles are 
additive and may be used to develop a 25(OH)D genetic risk score in 
MS patients (higher score represents a higher possibility of low 25(OH)
D). This vitamin D risk score could increase awareness of the risk of 
deficiency in MS patients in the absence of 25(OH)D measurement. 
The results indicated that the cumulative number of risk alleles predict 
lower 25(OH)D levels in CIS/RRMS patients. 
Vitamin D and Interferon β
Studies in animal models of MS, randomised clinical trials and cohort 
studies have assessed whether there is an association between 
vitamin D and IFNβ. The 1,25[OH][2]D[3] analogue, TX527 (19-nor-
14,20-bisepi-23-yne-1-1,25[OH][2]D[3]) has diminished calcemic 
effects but enhanced anti-proliferative and pro-differentiating 
properties on normal and malignant cell types in vivo compared 
with 1,25[OH][2]D[3].15 Studies in an experimental autoimmune 
encephalomyelitis (EAE) animal model demonstrated that TX527 
attenuates EAE.16 Further studies evaluated combinations of 
TX527, IFNβ and cyclosporine A in this model and showed that the 
combination of TX527 and IFNβ was significantly more effective in 
ameliorating the disease than either treatment alone. In addition, 
there was no effect with IFNβ and cyclosporine A but when TX527 was 
added to this combination virtually complete protection occurred. 
The authors suggested that the effect of IFNβ and TX527 should be 
evaluated in a clinical trial of MS.16
The safety and efficacy of adding vitamin D3 to IFNβ-1b treatment was 
assessed in a double-blind, placebo-controlled, randomised trial in 66 
MS patients over 1 year.17 In treated patients, the median change in 
T2 burden of disease was reduced in treated patients (83 mm3 versus 
287 mm3 in the placebo group). Levels of 25(OH)D in serum increased 
with 84  % of patients achieving >85  nmol/L in the IFNβ-1b group 
compared with placebo (p<0.0001). In addition, there was a trend 
towards a reduction in disability accumulation and improved timed 
tandem walk in the treatment group with no significant difference in 
annual relapse rate or adverse events.17
In a prospective cohort comprising 178 patients with clinically 
definite MS (CDMS), Stewart et al. measured 25(OH)D levels in serum 
twice a year together with a direct patient review and a questionnaire 
regarding sun exposure and relapse information in order to determine 
if IFNβ treatment was associated with vitamin D levels and if they 
interact with respect to relapse rate.18 Patients treated with IFNβ had 
significantly higher mean 25(OH)D levels than non-treated patients 
(p<0.001). This was mediated by an interaction between a patient’s 
sun exposure and IFNβ therapy, with treated patients achieving 
approximately three times the amount of 25(OH)D for each hour of 
sun exposure than those not on therapy. Furthermore, there was 
an association between 25(OH)D and reduced relapse risk only in 
treated patients (p<0.001). The reduction in relapse rate was only 
seen in IFNβ-treated patients with higher 25(OH)D levels whereas in 
those with insufficiency the relapse rate increased. These findings 
suggest that some of the therapeutic effects of IFNβ on relapse may 
be mediated through modulation of vitamin D metabolism. It could 
therefore be beneficial to monitor vitamin D status and supplement 
if necessary in patients treated with IFNβ.18 
Reder et al. investigated whether vitamin D enhanced IFNβ signalling by 
studying in vitro intracellular IFNβ response to combinations of vitamin 
2.0
Re
la
tiv
e 
ra
te
 o
f c
um
ul
at
iv
e 
N
A
Ls
1.0
1.5
0.5
0
20 40 60
25-Dihydroxyvitamin D, nmol/L
North America
Western Europe
Eastern Europe
Southern hemisphere
80 110100
Figure 3: Relative Rate of Cumulative New 
Active Lesions versus Average Baseline, 6- and 
12-month 25(OH)D Level Stratification by 
Geographic Region – BEYOND Study
The solid lines and shaded regions represent the relative rate ratios of cumulative new 
active lesions (NALs). NALs for changes in 25-hydroxyvitamin D (25(OH)D) relative to the 
median level and the corresponding 95 % confidence intervals, respectively. Analyses 
were adjusted for age, sex, randomisation status, baseline Expanded Disability Status 
Scale score and disease duration (1, 2–5, 6–10 and >10 years). Models assume a linear 
association between the logarithm of the rate of cumulative NALs and serum 25(OH)D. 
Analyses using cubic splines revealed no significant deviation from linearity. To convert 
25(OH)D values to nanograms per millilitre, divide by 2.496. BEYOND = Betaferon/
Betaseron Efficacy Yielding Outcomes of a New Dose in multiple sclerosis. Source: 
Reproduced with permission from Fitzgerald et al., 2015.11 
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D and IFNβ in treatment-naïve RRMS and progressive MS patients and 
those receiving IFNβ or GA.19 Vitamin D enhanced IFNβ activation of 
STAT1 by 30–70 % in untreated patients and by 30–150 % in those 
treated with IFNβ, but with only modest effects with GA. This increase 
in IFN signaling may provide a mechanism for the benefits of vitamin 
D in preventing and ameliorating MS, both before and during IFNβ-
1b treatment. Vitamin D may also help overcome the effects of low 
intrinsic serum IFN-α and β levels in MS.20
A study of RRMS patients treated with IFNβ and given vitamin D at either 
800 or 4,370 IU/day assessed for the post-injection cytokine surge that 
is associated with flu-like symptoms.21 In the low-dose group, serum IL-
17 increased significantly (p=0.037) but the response was inconsistent 
in the high-dose group with 40 % having decreased IL-17 levels and 
45 % increased levels. No significant changes occurred in the serum 
concentration of IL-10 and IFN-α. These results showed no benefit 
of vitamin D supplementation on flu-like symptoms but illustrate its 
immunomodulatory properties. 
Conclusion
Vitamin D status was assessed in patients who participated in the 
BENEFIT and BEYOND studies in order to explore the relationship 
between serum vitamin D level and the disease course. In the 
BENEFIT patients, serum 25(OH)D level predicted MS activity and 
progression. There appeared to be a correlation with serum 25(OH)
D levels ≥50  nmol/L and a positive benefit. The findings indicate the 
potential benefit of identifying patients with vitamin D insufficiency and 
correcting it. Furthermore, results from the BENEFIT cohort suggest 
that vitamin D and IFNβ-1b have an additive effect on disease activity.8,9
Similarly in the BEYOND study cohort, serum 25(OH)D levels had an 
inverse association with MRI markers of MS disease activity, which was 
similar in those from different locations and with various demographic 
and clinical characteristics. There was a non-significant association 
with relapses possibly as a result of the low relapse rate and relatively 
short follow-up period. 
Preliminary results in EAE suggest that vitamin D has a synergistic 
effect with IFNβ. Furthermore IFNβ has an additive effect with 25(OH)D 
on changes in gene expression known to reduce gadolinium-enhancing 
lesion counts, which suggests that improving vitamin D levels in 
such MS patients may be beneficial. 25(OH)D also shows systemic 
gene expression regulation on 25(OH)D target gene sets. Moreover, 
GWAS studies have identified candidate SNPs that were significantly 
associated with 25(OH)D levels.
Many studies of vitamin D and MS have caveats, which potentially 
cast doubts on their validity. There is a general consensus that better-
designed trials are needed to establish more robust evidence – especially 
multicentre, randomised, controlled, clinical trials using clinical, 
immunological and MRI outcomes. To address this problem Efficacy of 
Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS), a German, 
multicentre, stratified, randomised, controlled, double-blind, phase II trial 
was initiated.22 This trial aimed to randomise 80 CIS or RRMS patients 
treated with IFNβ-1b to 20, 400 or 400 IU 25(OH)D every other day for 
18 months. The primary endpoint is the cumulative number of new T2 
lesions on cranial MRI during the treatment period. Secondary endpoints 
include other MRI parameters, such as progression of brain atrophy 
over the study period and number and volume of T1-hypointense and 
T2-hyperintense lesions. As retinal thinning is increasingly recognised 
as a promising surrogate marker of tissue loss and neurodenegeration 
in MS, retinal nerve fibre layer thickness and macular volume measured 
by optical coherence tomography are additional secondary outcome 
parameters.23–25 The study has completed recruitment, however, results 
have not been published to date. Another such trial is the Supplementation 
of VigantOL® Oil (Merck KGaA, Darmstadt, Germany) versus placebo 
as add-on in patients with RRMS receiving Rebif® (Merck Serono S.A. – 
Geneva, Switzerland) treatment (SOLAR) study.26 This 96-week, three-arm, 
multicentre, double-blind, randomised, placebo-controlled phase  II trial 
will assess vitamin D3 (7,000 IU daily for 4 weeks then 14,000 daily for 
a further 92 weeks) as add-on therapy to subcutaneous IFNβ-1a 44 µg 
three times weekly in RRMS patients. The study aimed to randomise 348 
patients with RRMS and 25(OH)D serum levels <150 nmol/l in a 1:1 ratio 
to high-dose vitamin D3 versus placebo. A composite of clinical and MRI 
parameters was chosen as primary endpoint. The primary MRI endpoint 
is the mean number of combined unique active lesions at week 48 and 
the primary clinical endpoint the proportion of relapse-free patients at 
week 96.26 Several additional clinical and MRI endpoints will be assessed. 
This study has been completed, however, data have not yet been 
presented. The investigators anticipate that these studies will provide 
additional insights into the effect of vitamin D on IFN treatment. There is 
a lack of consensus concerning the definition of vitamin D deficiency and 
sufficiency both in the general population and in disorders such as MS. 
Until the results of the EVIDIMS and SOLAR studies are available, it would 
seem prudent that people with MS, regardless of their treatment status, 
have sufficient levels of vitamin D, according to local guidelines. There is 
growing evidence that this should be at least 50 nmol/L for those on IFNβ. 
It seems likely that there is an association between vitamin D levels 
and IFNβ treatment in MS patients with an additive benefit for the 
combination.27 Many studies have identified benefits on clinical 
and MRI measures in treating patients with both therapies. Ongoing 
clinical trials may provide more definitive evidence for this potentially 
beneficial combination.
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Figure 4: Concentration by Number of Risk 
Alleles – BENEFIT and BEYOND Studies 
25(OH)D = 25-hydroxyvitamin D; BENEFIT = BEtaferon/Betaseron in Newly Emerging 
multiple sclerosis For Initial Treatment; BEYOND = Betaferon/Betaseron Efficacy Yielding 
Outcomes of a New Dose in multiple sclerosis.Source: Reproduced with permission 
from Munger et al., 2014.14
EU Neuro Taylor_FINAL.indd   129 16/12/2015   23:47
130
Multiple Sclerosis
EUROPEAN NEUROLOGICAL REVIEW
Whether there may be a beneficial effect of a combination therapy of 
vitamin D3 with GA is under investigation in the Vitamin D to Ameliorate 
Multiple Sclerosis (VIDAMS) trial (NCT01490502).28 One hundred and 
seventy-two patients with RRMS are randomised in a 1:1 ratio to 5,000 IU 
or 600 IU oral vitamin D3 add on to GA over 96 weeks. The primary endpoint 
is the proportion of patients with a relapse at 2 years. Secondary and 
tertiary endpoints include additional clinical and MRI parameters. The 
study had not yet completed enrolment in spring 2015.29 ■
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